Jeanne Thoma Net Worth

The estimated Net Worth of Jeanne Thoma is at least $1.02 Million dollars as of 14 December 2023. Ms. Thoma owns over 9,612 units of ANI Pharmaceuticals Inc stock worth over $1,024,204 and over the last 4 years she sold ANIP stock worth over $0. In addition, she makes $0 as Independent Director at ANI Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Thoma ANIP stock SEC Form 4 insiders trading

Jeanne has made over 6 trades of the ANI Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 9,612 units of ANIP stock worth $522,124 on 14 December 2023.

The largest trade she's ever made was exercising 9,612 units of ANI Pharmaceuticals Inc stock on 14 December 2023 worth over $522,124. On average, Jeanne trades about 1,533 units every 57 days since 2020. As of 14 December 2023 she still owns at least 18,855 units of ANI Pharmaceuticals Inc stock.

You can see the complete history of Ms. Thoma stock trades at the bottom of the page.

Jeanne Thoma biography

Jeanne Thoma serves as Independent Director of the Company. Ms. Thoma is currently President and CEO of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. During her 30-year career, she has successfully built high-performing businesses that are agile, innovative and consistently deliver results. Prior to SPI, Ms. Thoma held positions of increasing responsibility at Lonza AG, a Switzerland-based biotech company, most recently as President and COO of the Microbial Control Business Sector. Prior to joining Lonza, Ms. Thoma spent 14 years at BASF Corp. in the Pharma Solutions business where she held various leadership positions in Sales, Marketing and Operations. Ms. Thoma is a member of the Board of Advisors for the Drug Chemical and Associated Technologies Association (DCAT).

How old is Jeanne Thoma?

Jeanne Thoma is 61, she's been the Independent Director of ANI Pharmaceuticals Inc since 2020. There are 3 older and 11 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.

What's Jeanne Thoma's mailing address?

Jeanne's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.

Insiders trading at ANI Pharmaceuticals Inc

Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... und Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.

What does ANI Pharmaceuticals Inc do?

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Complete history of Ms. Thoma stock trades at ANI Pharmaceuticals Inc und Avid Bioservices Inc

ANI Pharmaceuticals Inc executives and stock owners

ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Schrepfer,
  Senior Vice President - New Business Development and Specialty Sales
• Stephen Carey,
  Corporate Secretary, Vice President, Finance and Chief Financial Officer
• James Marken,
  Senior Vice President - Operations and Product Development
• James G. Marken,
  Sr. VP of Operations & Product Devel.
• Robert Brown,
  Independent Director
• Thomas Haughey,
  Independent Director
• Thomas Penn,
  Independent Director
• Patrick Walsh,
  Chairman of the Board
• David Nash,
  Independent Director
• Jeanne Thoma,
  Independent Director
• Antonio Pera,
  Independent Director
• Nikhil Lalwani,
  President, Chief Executive Officer, Director
• Muthasamy Shanmugam MS R.Ph.,
  Head of R&D and COO of Novitium Operations
• Ori Gutwerg,
  Sr. VP of Generics
• Christopher K. Mutz,
  Head of Rare Diseases
• Chad Gassert,
  Sr. VP of Corp. Devel. & Strategy
• Daniel Raynor,
  Director
• Arthur Przybyl,
  President and CEO
• Tracy Marshbanks,
  Director
• Fred Holubow,
  Director
• Peter A Lankau,
  Director
• Charlotte C. Arnold,
  Chief Financial Officer
• Renee P Tannenbaum,
  Director
• Ross J Mangano,
  Director
• Robert J. Jamnick,
  VP, Quality & Product Develop.
• Venture Partners Ii Lp Meri...,
  
• Ori Gutwerg,
  SVP, GENERICS
• Christopher Mutz,
  HEAD OF RARE DISEASE
• Krista Davis,
  SVP, CHIEF HR OFFICER
• Chad Gassert,
  SVP - CORP. DEV. & STRATEGY
• Meredith Cook,
  SR. VP, GENERAL COUNSEL & SEC.
• Muthusamy Shanmugam,
  HEAD OF R&D, COO-NOVITIUM OPS
• Matthew J Leonard,
  Director